Save Product
Product Details
Synonyms
TIGIT, VSIG9, VSTM3
Source
Rat TIGIT, Fc Tag (TIT-R5258) is expressed from human 293 cells (HEK293). It contains AA Ala 17 - Ala 138 (Accession # D3ZTQ2).
Predicted N-terminus: Ala 17
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 39.9 kDa. The protein migrates as 48-55 kDa under reducing (R) condition, and 85-110 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Rat TIGIT, Fc Tag on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Bioactivity-ELISA
Immobilized Human Nectin-2, His Tag (Cat. No. PV2-H52E2) at 5 μg/mL (100 μL/well) can bind Rat TIGIT, Fc Tag (Cat. No. TIT-R5258) with a linear range of 0.039-5 μg/mL (QC tested).
Protocol
Bioactivity-BLI
Loaded Rat TIGIT, Fc Tag (Cat. No. TIT-R5258) on Protein A Biosensor, can bind Human Nectin-2, His Tag (Cat. No. PV2-H52E2) with an affinity constant of 0.59 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
T cell immunoglobulin and ITIM domains
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
41 Details
- Highest Development Stage：
Phase 3 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
